Cancer Stem Cell Mechanotransduction in Engineered Matrix

工程基质中的癌症干细胞机械转导

基本信息

  • 批准号:
    1403545
  • 负责人:
  • 金额:
    $ 30万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
    Standard Grant
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-07-01 至 2018-06-30
  • 项目状态:
    已结题

项目摘要

PI: Jabbari, Esmaiel Proposal Number: 1403545Institution: University of South Carolina at ColumbiaTitle: Cancer Stem Cell Mechanotransduction in Engineered MatrixAmong different cancers, breast cancer is the most common type. A major contributing factor to mortality in cancer patients is the return of the cancer after chemotherapy. Cancer relapse affects 30% of breast cancer patients. Recent observations indicate that cancer relapse may be related to a very small population of slow-growing cancer stem cells (CSCs) in the tumor that are unaffected by chemotherapy. After chemotherapy, the bulk of the tumor shrinks to less than a few percent of the initial size, thus enriching the tumor with CSCs that do not respond to conventional therapies. The enriched CSCs divide, grow and regenerate the tumor volume, leading to cancer relapse or recurrence. Consistent with that notion, the triple negative cancer (TNBC), which is the most aggressive type of breast cancer, has the highest sub-population of CSCs among different breast cancer types with 77% survival rate, compared to 93% for other types, The broader significance of this project is understanding the role of those factors in the tumor environment that contribute the survival of CSCs. One of the factors that play a central role is the tumor tissue stiffness. For example, lumps in the breast that feel stiffer than the rest of the tissue are a sign of possible breast cancer that should be checked. The objective of this project was to determine the role of tissue stiffness on CSC survival and growth in a tissue-like three-dimensional matrix. The importance of this project lies in identifying new agents that target tissue stiffness to destroy CSCs and the development of a kit to test drugs against cancer stem cells. The PI will use several programs to recruit under-represented students and he will work with the South Carolina Children's museum to develop an interactive exhibit titled "hydrogels" for kids. This proposal is co-funded by the Biomedical Engineering Program in the Chemical, Bioengineering, Environmental and Transport Systems Division, and by the Biomaterials Program in the Division of Materials Research.Cancer relapse is related to a very small population of slow-growing cancer stem cells (CSCs) that do not respond to conventional therapies. Naturally derived matrices are widely used as a matrix to study CSC survival but due to many ligand-receptor interactions, the effect of mechanotransduction on CSC signaling pathways that maintain CSC cannot be investigated. The objective of this work is to engineer a matrix with defined properties to serve as a sieve for selection and enrichment of CSCs and to investigate the effect of matrix stiffness on intracellular pathways that maintain CSCs. The overall hypothesis is that in the absence of receptor-ligand interaction, matrix stiffness is the extracellular activator of YAP/TAZ through GPCR/lipid rafts/Rho/ROCK signaling pathway, leading to CSC survival. It is further hypothesized that in the presence of integrin-binding ligands, focal adhesion is the extracellular activator of Hippo through the FAK/Rac signaling pathway and stress fiber formation in the cell periphery, leading to the expression of LATS1/2 kinases, inhibition of YAP/TAZ transcription factors and loss of CSC maintenance. The following approach is used to test the hypothesis. In Aim 1, cancer cells will be encapsulated in the novel lactide-chain-extended polyethylene glycol (SPELA) hydrogel and cultured in a medium supplemented with Doxorubicin (Dox) and/or Salinomycin (Sal) to select and enrich for the most invasive CSC phenotype in the growing CSC colonies. In Aim 2, the effect of matrix stiffness on the activation of YAP/TAZ transcription factors through GPCR/lipid rafts/Rho/ROCK signaling pathway of CSC will be investigated with the enriched CSC colonies encapsulated in the SPELA hydrogel. And in Aim 3, the effect of conjugated integrin-binding ligands on the activation of Hippo signaling pathway of CSC will be investigated with the enriched CSC colonies encapsulated in the SPELA hydrogel with optimum stiffness. The intellectual merit of this work is a model engineered culture system to screen for the most effective drugs and targeting ligands against the most invasive CSC colonies. The broader impact of this work lies in generating a cancer stem cell-on-a-chip as a more relevant in vitro tumor model in basic research, drug discovery and personalized medicine.
主要研究者:贾巴里、伊斯梅尔 提案编号:1403545机构:南卡罗来纳州哥伦比亚大学题目:工程基质中的癌症干细胞机械转导在不同的癌症中,乳腺癌是最常见的类型。癌症患者死亡的一个主要因素是化疗后癌症的复发。癌症复发影响30%的乳腺癌患者。最近的观察表明,癌症复发可能与肿瘤中不受化疗影响的非常小的缓慢生长的癌症干细胞(CSC)群体有关。化疗后,肿瘤的体积缩小到小于初始大小的百分之几,从而使肿瘤富含对常规疗法无反应的CSC。富集的CSC分裂、生长和再生肿瘤体积,导致癌症复发或再发。与这一概念相一致,三阴性癌(TNBC)是最具侵袭性的乳腺癌类型,在不同的乳腺癌类型中具有最高的CSC亚群,存活率为77%,而其他类型为93%,该项目的更广泛意义在于了解这些因素在肿瘤环境中的作用,这些因素有助于CSC的存活。起核心作用的因素之一是肿瘤组织硬度。例如,乳房中感觉比其他组织更硬的肿块是可能的乳腺癌的迹象,应该进行检查。该项目的目的是确定组织硬度对CSC在组织样三维基质中生存和生长的作用。该项目的重要性在于确定靶向组织硬度以破坏CSC的新药物,并开发一种试剂盒来测试针对癌症干细胞的药物。 PI将使用几个项目来招募代表性不足的学生,他将与南卡罗来纳州儿童博物馆合作,为孩子们开发一个名为“水凝胶”的互动展览。 该提案由化学、生物工程、环境和运输系统部门的生物医学工程项目和材料研究部门的生物材料项目共同资助。癌症复发与非常小的缓慢生长的癌症干细胞(CSC)群体有关,这些干细胞对传统疗法没有反应。天然来源的基质被广泛用作研究CSC存活的基质,但由于许多配体-受体相互作用,无法研究机械转导对维持CSC的CSC信号传导途径的影响。 这项工作的目的是设计一种具有确定性质的基质,作为筛选和富集CSC的筛子,并研究基质硬度对维持CSC的细胞内途径的影响。总体假设是,在缺乏受体-配体相互作用的情况下,基质硬度是雅普/TAZ通过GPCR/脂筏/Rho/ROCK信号通路的细胞外激活剂,导致CSC存活。进一步假设,在存在整合素结合配体的情况下,粘着斑是Hippo通过FAK/Rac信号通路和细胞外周中的应力纤维形成的细胞外激活剂,导致LATS 1/2激酶的表达、雅普/TAZ转录因子的抑制和CSC维持的丧失。以下方法用于检验假设。在目标1中,将癌细胞包封在新型丙交酯链延长的聚乙二醇(SPELA)水凝胶中,并在补充有多柔比星(Dox)和/或盐霉素(Sal)的培养基中培养,以在生长的CSC集落中选择和富集最具侵袭性的CSC表型。在目的2中,将用包封在SPELA水凝胶中的富集的CSC集落研究基质刚度对通过CSC的GPCR/脂筏/Rho/ROCK信号传导途径激活雅普/TAZ转录因子的影响。在目标3中,将用包封在具有最佳刚度的SPELA水凝胶中的富集的CSC集落研究缀合的整合素结合配体对CSC的Hippo信号传导途径的活化的影响。这项工作的智力价值是一个模型工程培养系统,以筛选最有效的药物和靶向配体对最具侵袭性的CSC集落。这项工作的更广泛的影响在于产生癌症干细胞芯片,作为基础研究,药物发现和个性化医疗中更相关的体外肿瘤模型。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Esmaiel Jabbari其他文献

Mapping the concentration profile at the poly(vinyl chloride)/poly(ethyl methacrylate) interface
  • DOI:
    10.1007/bf00294536
  • 发表时间:
    1991-12-01
  • 期刊:
  • 影响因子:
    4.000
  • 作者:
    Esmaiel Jabbari;Nicholas A. Peppas
  • 通讯作者:
    Nicholas A. Peppas
Release characteristics of a model plasmid DNA encapsulated in biodegradable poly(ethylene glycol fumarate)/acrylamide hydrogel microspheres
封装在可生物降解的聚(富马酸乙二醇酯)/丙烯酰胺水凝胶微球中的模型质粒 DNA 的释放特性
  • DOI:
    10.1080/02652040410001729296
  • 发表时间:
    2004
  • 期刊:
  • 影响因子:
    3.9
  • 作者:
    Esmaiel Jabbari
  • 通讯作者:
    Esmaiel Jabbari
Advances in tannic acid-incorporated biomaterials: Infection treatment, regenerative medicine, cancer therapy, and biosensing
单宁酸结合生物材料的进展:感染治疗、再生医学、癌症治疗和生物传感
  • DOI:
    10.1016/j.cej.2021.134146
  • 发表时间:
    2022-03-15
  • 期刊:
  • 影响因子:
    13.200
  • 作者:
    Ashkan Bigham;Vahid Rahimkhoei;Payam Abasian;Masoud Delfi;Jamal Naderi;Matineh Ghomi;Farnaz Dabbagh Moghaddam;Tayyab Waqar;Yavuz Nuri Ertas;Sina Sharifi;Navid Rabiee;Sezgin Ersoy;Aziz Maleki;Ehsan Nazarzadeh Zare;Esmaeel Sharifi;Esmaiel Jabbari;Pooyan Makvandi;Ali Akbari
  • 通讯作者:
    Ali Akbari

Esmaiel Jabbari的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Esmaiel Jabbari', 18)}}的其他基金

PFI:AIR - TT: Biomimetic Composite for Segmental Bone Regeneration
PFI:AIR - TT:用于节段骨再生的仿生复合材料
  • 批准号:
    1500242
  • 财政年份:
    2015
  • 资助金额:
    $ 30万
  • 项目类别:
    Standard Grant
I-Corps: Biomimetic Degradable Load Bearing Osteoconductive Bone Graft
I-Corps:仿生可降解承重骨传导骨移植物
  • 批准号:
    1357109
  • 财政年份:
    2013
  • 资助金额:
    $ 30万
  • 项目类别:
    Standard Grant
Microengineered Osteon-Mimetic Composite
微工程仿骨复合材料
  • 批准号:
    1049381
  • 财政年份:
    2010
  • 资助金额:
    $ 30万
  • 项目类别:
    Continuing Grant
Engineered Nanoparticles for Tumor Targeting
用于肿瘤靶向的工程纳米颗粒
  • 批准号:
    0931998
  • 财政年份:
    2009
  • 资助金额:
    $ 30万
  • 项目类别:
    Standard Grant
Engineering Bone Formation in Multi-Functional Nanocomposite Scaffolds
多功能纳米复合支架中的工程骨形成
  • 批准号:
    0756394
  • 财政年份:
    2008
  • 资助金额:
    $ 30万
  • 项目类别:
    Continuing Grant

相似国自然基金

过渡金属氧化物电催化CO2性能的原位4D-STEM研究
  • 批准号:
  • 批准年份:
    2024
  • 资助金额:
    0.0 万元
  • 项目类别:
    省市级项目
基于图谱补全与评价循证的中学STEM课程资源智能组织方法研究
  • 批准号:
    62307023
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
利用iDPC-STEM与冷冻电子断层成像技术相结合的方式解析生物厚样品原位高分辨三维结构
  • 批准号:
    32241024
  • 批准年份:
    2022
  • 资助金额:
    100.00 万元
  • 项目类别:
    专项项目
科学传播类:跨学科STEM科普活动实践与科技创新人才培养机制研究
  • 批准号:
    T2241013
  • 批准年份:
    2022
  • 资助金额:
    10.00 万元
  • 项目类别:
    专项项目
调控胰岛特异性stem-like CD8+ Tm细胞能量代谢免疫治疗1型糖尿病研究
  • 批准号:
    82230028
  • 批准年份:
    2022
  • 资助金额:
    261 万元
  • 项目类别:
    重点项目
STEM教育情境下多人同伴互动的脑协同机制与策略研究
  • 批准号:
    62177011
  • 批准年份:
    2021
  • 资助金额:
    47 万元
  • 项目类别:
    面上项目
线粒体tRNA ACC-stem突变在母系遗传性高血压发病中的功能及机制研究
  • 批准号:
    82070434
  • 批准年份:
    2020
  • 资助金额:
    54 万元
  • 项目类别:
    面上项目
基于STEM的异质结构变形测试方法与晶格结构重构技术研究
  • 批准号:
    12002116
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
STEM三维云纹法及在单晶高温合金损伤行为研究中的应用
  • 批准号:
    11972084
  • 批准年份:
    2019
  • 资助金额:
    68.0 万元
  • 项目类别:
    面上项目
基于激光与管电极电解同步复合(Laser-STEM)的低损伤大深度小孔加工技术基础研究
  • 批准号:
    51905525
  • 批准年份:
    2019
  • 资助金额:
    26.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Engineering the bone marrow niche to control stem cell regulation, metastatic evolution and cancer dormancy
改造骨髓生态位来控制干细胞调节、转移进化和癌症休眠
  • 批准号:
    EP/X036049/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30万
  • 项目类别:
    Research Grant
腸脳相関によるサイトカインを中心とした膠芽腫Cancer Stem Cell Theoryの解明
通过肠-脑相关性阐明以细胞因子为中心的胶质母细胞瘤癌症干细胞理论
  • 批准号:
    24K12244
  • 财政年份:
    2024
  • 资助金额:
    $ 30万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Role of AMIGO2 in acquisition of cancer stem cell properties and identification of inhibitory compounds
AMIGO2 在获取癌症干细胞特性和识别抑制化合物中的作用
  • 批准号:
    23K06482
  • 财政年份:
    2023
  • 资助金额:
    $ 30万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Oncogenic Drivers of Rhabdomyosarcoma Cell State, Cancer Stem Cells and Metastasis
横纹肌肉瘤细胞状态、癌症干细胞和转移的致癌驱动因素
  • 批准号:
    10658091
  • 财政年份:
    2023
  • 资助金额:
    $ 30万
  • 项目类别:
Elucidation of the diversity and treatment resistance of multiple breast cancer stem cell populations
阐明多种乳腺癌干细胞群的多样性和治疗耐药性
  • 批准号:
    23K06665
  • 财政年份:
    2023
  • 资助金额:
    $ 30万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Elucidation of the pathogenesis of cancer stem cell transformation and acquisition of therapeutic resistance in lung cancer via the Hedgehog signaling system
通过 Hedgehog 信号系统阐明肺癌干细胞转化和获得治疗耐药性的发病机制
  • 批准号:
    23K08304
  • 财政年份:
    2023
  • 资助金额:
    $ 30万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Elucidation of stem cell motility mechanism and its application to regeneration and cancer therapy
阐明干细胞运动机制及其在再生和癌症治疗中的应用
  • 批准号:
    23K07820
  • 财政年份:
    2023
  • 资助金额:
    $ 30万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Ferroptosis in Mesenchymal Stem Cell in Metastasis of pancreatic cancer
胰腺癌转移中间充质干细胞的铁死亡
  • 批准号:
    23K15442
  • 财政年份:
    2023
  • 资助金额:
    $ 30万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Identification of a novel targetable cancer stem cell regulator promoting cancer progression and metastasis in non-small cell lung cancer
鉴定一种新型靶向癌症干细胞调节剂,促进非小细胞肺癌的癌症进展和转移
  • 批准号:
    10594368
  • 财政年份:
    2023
  • 资助金额:
    $ 30万
  • 项目类别:
Identification of a novel targetable cancer stem cell regulator promoting cancer progression and metastasis in non-small cell lung cancer
鉴定一种新型靶向癌症干细胞调节剂,促进非小细胞肺癌的癌症进展和转移
  • 批准号:
    10907315
  • 财政年份:
    2023
  • 资助金额:
    $ 30万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了